Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics.
about
Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9aThe emerging role of lysine methyltransferase SETD8 in human diseasesSynergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasRecent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.Small-molecule modulators for epigenetics targets.A chemical proteomics approach for global analysis of lysine monomethylome profiling.Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2.Genetic alterations of histone lysine methyltransferases and their significance in breast cancerQuantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma.Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.Epigenetics in cancer stem cells.Targeting epigenetic regulators for cancer therapy.Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.Exploring the epigenetic drug discovery landscape.Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors.Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors.Identification and characterization of PKF118-310 as a KDM4A inhibitor.Conference scene: 2nd cancer epigenetics conference.High-Throughput Block Optical DNA Sequence Identification.Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
P2860
Q27684229-BE8CBC41-C21E-4DAA-BC88-A4BEB9C4F957Q28079964-37CAA3B6-71F0-4DD8-BFC3-3EEB892F2E2DQ34670913-1CCEF722-68F7-4CD8-A659-306C5EE2C6AFQ34991896-990F671F-30D8-4D48-9FC3-149979AC3243Q35017572-EE7BCFF0-517E-45F7-8B4B-D57499EBC535Q35148553-B7BACBCD-5427-45D3-A5FA-6F3284EC099FQ35228394-7E231371-3A91-4C1F-9079-A5FA2D01EC13Q35273743-9F1CD1A6-64FB-4190-8BE0-6BF2FAF034E0Q35437107-267172DC-9361-4503-8A25-37D3B233343CQ35800914-F7F28099-462E-4A9F-868E-4A1353931079Q35820972-1347DE82-4529-4CF1-AB68-3B540494E948Q37190344-FEBC827A-FFAA-482B-BEF2-6A9F38E0D5A3Q37618640-B8720461-5FDF-4C90-A741-1EDC0D84E87BQ38191266-30FBAE05-B8AB-42B4-B79D-AE88D487B618Q38725254-56767D90-0A6F-4165-AB71-DB6045A4ADB5Q38748410-5FDF8D4D-3EDD-42D7-A36A-9636930C6E60Q38833038-946CDBD0-ED5A-4BA9-99A4-1D4C1A0FA214Q38895557-023B2278-AE25-4053-8B97-02FD407FF7D7Q42064958-0109118A-AA12-4424-8AA8-7267610FE26EQ42358298-1C1BD5C2-D9BD-469B-90E1-BCA44E18BC1CQ46859945-7B2F8B42-C2BA-4051-8127-D9CF480D6498Q47283403-5EBD488A-7105-49D9-9374-B4B6C1308EE0Q52342542-99B46F14-E03C-4BED-8922-2D7C002FBF75
P2860
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting genetic alterations ...... sonalized cancer therapeutics.
@en
type
label
Targeting genetic alterations ...... sonalized cancer therapeutics.
@en
prefLabel
Targeting genetic alterations ...... sonalized cancer therapeutics.
@en
P2093
P2860
P356
P1433
P1476
Targeting genetic alterations ...... sonalized cancer therapeutics.
@en
P2093
R A Copeland
V M Richon
P2860
P2888
P304
P356
10.1038/ONC.2012.552
P407
P5008
P577
2012-11-19T00:00:00Z
2013-02-21T00:00:00Z
P5875
P6179
1034048021